Back

EXO1 Facilitates MiDAS and Prevents Genome Instability and Cell Death in Ewing Sarcoma

Olmedo-Pelayo, J.; Lobo-Selma, L.; Delgado-Bellido, D.; Jordan-Perez, C.; Gilabert-Prieto, P.; Perez, M.; Geyer, F. H.; Carreno-Gonzalez, M. J.; Alonso, J.; Zheng, L.; Shen, B.; Grunewald, T. G. P.; Gomez Herreros, F.; de Alava, E.

2026-06-09 cancer biology
10.64898/2026.06.05.730187 bioRxiv
Show abstract

Ewing sarcoma (EwS) is an aggressive malignancy driven by EWSR1::ETS fusions, predominantly EWSR1::FLI1. Previous efforts using both direct and indirect approaches to target these chimeric oncoproteins have yielded limited clinical benefit. Although EWSR1::FLI1 is a well-known source of replication stress and genome instability, targeting DNA damage response (DDR) factors that mitigate these effects remain poorly understood. Here, we identified a marked dependency of EwS cells on exonuclease 1 (EXO1). We demonstrate that EXO1 is essential for EwS cell survival and tumor growth, highlighting its potential as a novel therapeutic target. Intriguingly, we unveil that EXO1 loss impairs mitotic DNA synthesis (MiDAS), promoting EWSR1::FLI1-associated genome instability and cell death. Collectively, our results support the idea that targeting DDR factors, which counteract replication stress and/or DNA damage induced by fusion oncoproteins, represents a promising therapeutic option for EwS.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Oncogene
85 papers in training set
Top 0.1%
12.9%
2
Nature Communications
5641 papers in training set
Top 18%
9.8%
3
Clinical Cancer Research
64 papers in training set
Top 0.2%
7.9%
4
Cell Death & Disease
21 papers in training set
Top 0.1%
5.5%
5
Molecular Cancer Research
49 papers in training set
Top 0.2%
4.0%
6
Cancers
213 papers in training set
Top 2%
3.2%
7
Journal of Clinical Investigation
179 papers in training set
Top 1%
3.2%
8
Cell Reports
1498 papers in training set
Top 12%
3.2%
9
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 16%
3.2%
50% of probability mass above
10
Molecular Cancer Therapeutics
40 papers in training set
Top 0.3%
2.6%
11
Cancer Research Communications
51 papers in training set
Top 0.5%
2.6%
12
Cancer Research
130 papers in training set
Top 2%
2.1%
13
eLife
5828 papers in training set
Top 49%
1.7%
14
Science Translational Medicine
127 papers in training set
Top 2%
1.7%
15
Molecular Therapy Oncology
10 papers in training set
Top 0.1%
1.7%
16
JCI Insight
277 papers in training set
Top 4%
1.7%
17
Scientific Reports
3612 papers in training set
Top 58%
1.5%
18
Disease Models & Mechanisms
20 papers in training set
Top 0.2%
1.5%
19
npj Precision Oncology
53 papers in training set
Top 1.0%
1.5%
20
Science Advances
1243 papers in training set
Top 21%
1.5%
21
Communications Biology
993 papers in training set
Top 19%
1.3%
22
EMBO Molecular Medicine
95 papers in training set
Top 2%
1.1%
23
iScience
1154 papers in training set
Top 25%
1.1%
24
NAR Cancer
37 papers in training set
Top 0.6%
0.9%
25
The Journal of Pathology
26 papers in training set
Top 0.8%
0.8%
26
Leukemia
42 papers in training set
Top 0.7%
0.8%
27
Genome Medicine
183 papers in training set
Top 5%
0.8%
28
Blood
74 papers in training set
Top 1%
0.8%
29
Theranostics
37 papers in training set
Top 1%
0.6%
30
Molecular Oncology
55 papers in training set
Top 2%
0.6%